Personalizing radiotherapy dose based on tumor biology has been an important research direction in head and neck cancer.
The phase III ARTFORCE trial tested whether FDG-PET-guided adaptive dose-redistributed radiotherapy could improve outcomes in patients with locally advanced head and neck squamous cell carcinoma without increasing toxicity.
A new final analysis published in Radiotherapy and Oncology reports acute toxicity, five-year toxicity, and five-year oncologic outcomes from the trial.
Why This Study Matters
Locally advanced head and neck squamous cell carcinoma is often treated with definitive chemoradiotherapy.
One major challenge is how to improve locoregional control while avoiding additional toxicity in a region where treatment can affect swallowing, speech, airway function, nutrition, and long-term quality of life.
FDG-PET-guided radiotherapy aims to identify metabolically active tumor regions and adapt radiation dose distribution accordingly.
The ARTFORCE trial tested whether this strategy could safely improve tumor control compared with conventional chemoradiotherapy.
Study Design
ARTFORCE was a multicenter randomized phase III trial.
Patients with T3–4, N0–3, M0 locally advanced head and neck squamous cell carcinoma were randomized 1:1 to receive either FDG-PET-guided adaptive dose-redistributed radiotherapy or conventional radiotherapy.
The experimental arm received 64–84 Gy in 35 fractions, with adaptation at fraction 10.
The conventional arm received 70 Gy in 35 fractions.
Both groups received concurrent cisplatin at 100 mg/m² for three cycles.
The updated report focused on acute toxicity, five-year toxicity, locoregional control, progression-free survival, overall survival, and exploratory subgroup findings.
Patient Population
The trial closed after reaching 84% of planned accrual because of slow recruitment.
A total of 221 eligible patients were included.
There were 109 patients in the FDG-PET-guided dose-redistributed radiotherapy arm and 112 patients in the conventional radiotherapy arm.
The study population included patients with stage III–IV, nonmetastatic, locally advanced head and neck squamous cell carcinoma.
Key Results
At five years, FDG-PET-guided adaptive dose-redistributed radiotherapy did not significantly improve locoregional control compared with conventional radiotherapy.
The five-year locoregional control result was consistent with the previously reported two-year findings.
The hazard ratio for locoregional control was 0.78, with a 95% confidence interval of 0.45 to 1.36.
This difference was not statistically significant.
Progression-free survival and overall survival were also similar between the two treatment approaches.
Toxicity Results
Acute toxicity rates were similar between the treatment arms.
Long-term toxicity was also broadly comparable between FDG-PET-guided dose-redistributed radiotherapy and conventional radiotherapy.
One important difference was a higher rate of grade 3 or higher pharyngolaryngeal stenosis in the experimental arm.
No other major toxicity differences were identified.
Most toxicities stabilized after two years, although hypothyroidism and fibrosis continued to increase during the five-year follow-up period.
Subgroup Findings
Exploratory subgroup analyses suggested possible trends favoring FDG-PET-guided dose-redistributed radiotherapy in patients with oropharyngeal cancer and N0–1 disease.
However, these findings were exploratory and did not identify a clear subgroup that definitively benefited from the experimental strategy.
The final analysis therefore does not support routine use of FDG-PET-guided dose redistribution for all patients with locally advanced head and neck squamous cell carcinoma.
Clinical Interpretation
The ARTFORCE trial provides important long-term evidence for FDG-PET-guided adaptive radiotherapy in head and neck cancer.
The strategy appeared feasible and did not lead to broad increases in acute or late toxicity compared with conventional treatment.
However, it also did not significantly improve tumor control or survival.
This distinction is important.
The trial supports the long-term safety of FDG-PET-guided dose redistribution, but not its general clinical superiority over standard chemoradiotherapy.
The increased rate of severe pharyngolaryngeal stenosis in the experimental arm also highlights the need for careful dose planning and long-term functional follow-up when testing dose-escalation or dose-redistribution strategies in head and neck cancer.
Limitations
The trial closed before reaching full planned accrual, which may have reduced statistical power.
The subgroup findings were exploratory and should not be interpreted as definitive evidence of benefit.
As treatment techniques, systemic therapy, imaging, HPV-associated disease biology, and adaptive radiotherapy workflows continue to evolve, future studies may need more refined patient selection and toxicity-sensitive endpoints.
Clinical Takeaway
The final ARTFORCE analysis confirms that FDG-PET-guided adaptive dose-redistributed radiotherapy has similar long-term toxicity, tumor control, and survival compared with conventional chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
The approach appears safe overall, but it did not significantly improve oncologic outcomes.
For now, the results support continued research into biologically guided radiotherapy, while emphasizing the importance of patient selection, functional toxicity monitoring, and long-term follow-up.
Read full article here.
